Automated office and home phone-transmitted blood pressure recordings in uncontrolled hypertension treated with valsartan and hydrochlorothiazide

Blood Pressure, Supplement

Volumn 13, Issue 2, 2004, Pages 18-24

  Girerd, Xavier ^a   Denolle, Thierry ^b   Yau, Caroline ^c   Fiquet, Béatrice ^c   Brunel, Patrick ^c,d   Moulin, Bruno ^b   Herpin, Daniel ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Novartis Pharma SAS ^*

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d NOVARTIS PHARMA K K   (Japan)

Author keywords

Home blood pressure recordings; Hydrochlorothiazide; Hypertension; Phone transmission; Valsartan

Indexed keywords

ANGIOTENSIN ANTAGONIST; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; HYDROCHLOROTHIAZIDE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN;

ADULT; AGED; ARTICLE; ASTHENIA; AUTOMATION; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRONCHITIS; CLINICAL TRIAL; DIAGNOSTIC VALUE; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; EVALUATION; FEMALE; HOME MONITORING; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; OPEN STUDY; OSCILLOMETRY; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TELECOMMUNICATION; TELEPHONE; VALIDATION PROCESS; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; DRUG ANTAGONISM; DRUG COMBINATION; METHODOLOGY; MIDDLE AGED; TIME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; AUTOMATION; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; OSCILLOMETRY; RECEPTORS, ANGIOTENSIN; TELEPHONE; TETRAZOLES; TIME FACTORS; VALINE;

EID: 17844410118     PISSN: 08038023     EISSN: None     Source Type: Journal    
DOI: 10.1080/08038020410004756     Document Type: Article

References (33)

1. Lang T, de Gaudemaris R, Chatellier G, Hamici L, Diene E. Prevalence and therapeutic control of hypertension in 30000 subjects in the workplace. Hypertension 2001; 38: 449-54.
2. Girerd X, Mourad JJ, Vaïsse B, Poncelet P, Mallion JM, Herpin D. Estimation of the number of patients treated for hypertension, diabetes or hyperlipidemia in France: FLAHS study 2002. Arch Mal Coeur Vaiss 2003; 96: 750-3.
3. 2003 European Society of Hypertension - European Society of Cardiology. Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
4. The Seven Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-72.
5. Hitzenberger G, Magometschnigg D. Blood pressure characteristics of hypertensive patients in Austria as determined by self-monitoring (SCREEN-11). Blood Press 2003; 12: 134-8.
6. Sever PA, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al for the ASCOT investigators. The prevention of coronary events and stroke with atorvastatine in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT: LLA). Lancet 2003; 361: 1149-58.
7. Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR. Hypertension control: How well are we doing? Arch Intern Med 2003: 163: 2705-11.
8. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427-31.
9. Muldoon FM, Rutan GH. Defining hypertension never as simple as it seems. J Hypertens 2003; 21: 473-4.
10. Mengden T, Vetter H, Tisler A, Illyes M. Tele-monitoring of home blood pressure. Blood Press Monit 2001; 6: 185-9.
11. Deak G, Nemeth Z, Moczar K. Validation of the 24-hour ambulatory blood pressure monitor TensioDay according to the AAMI (1993) and BHS (1993). Report from the 1st Department of Medicine Semmelweis University Budapest, Hungary, 2000.
12. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
13. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. J Hypertens 2003; 21: 821-48.
14. Cirëe A, Hanon O, Bureau JM, Mourad JJ, Girerd X. Influence du protocole sur la qualitë de l'automesure tensionnelle. Archiv Mal Coeur 2001; 94: 893-6.
15. Mengden T, Hernandez Medine RM, Beltran B, Alvarez E, Kraft K, Vetter H. Reliability of self-measured blood pressure values by hypertensive patients. Am J Hypertens 1998; 11: 1413-17.
16. Stergiou G, Skeva I, Zourbaki A, Mountokalakis T. Self-monitoring of blood pressure at home: how many measurements are needed? J Hypertens 1998; 16: 725-31.
17. Herpin D, Pickering TG, Stergiou GS, De Leeuw P, Germano G. Self-blood pressure monitoring: clinical applications and diagnosis. Blood Press Monit 2000; 5: 131-5.
18. Parati G, Mancia G. White coat effect: semantics, assessment and pathophysiological implications. J Hypertens 2003; 21: 481-6.
19. Parati G, Stergiou G. Self measured and ambulatory blood pressure in assessing the 'white coat' phenomenon. J Hypertens 2003; 21: 677-82.
20. Mancia G, Korlipara K, van Rossum P, Villa G, Silvert B. An ambulatory blood pressure monitoring study of the comparative antihypertensive efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan. Blood Press Monit 2002; 7: 135-42.
21. Redon J, Lurbe E. Ambulatory blood pressure monitoring during antihypertensive treatment: the case of non-responder patients. Blood Press Monit 1996; 1: 299-303.
22. Wing LMH, Brown MA, Beilin LJ, Ryan P, Reid CM On behalf of the ANBP2 Management Committee and Investigators. 'Reverse white coat hypertension' in older hypertensives. J Hypertens 2002; 20: 639-44.
23. Pickering T, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension 2002; 40: 795-6.
24. Chatellier G, Dutrey-Dupagne C, Vaur L, Zannad F, Genes N, Elkik F, et al. Home self blood pressure measurement in general practice. The SMART study. Self-measurement for the assessment of the response to trandolapril. Am. J. Hypertens 1996; 9: 644-52.
25. BeIz G. Pharmacological differences among angiotensine II receptor antagonists. Blood Press 2001; 10 Suppl 2: 13-18.
26. Benz JR, Black HR, Graff A, Reed A, Fitzsimmon S, Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind placebo-controlled trial comparing combination therapy with monotherapy. J Human Hypertens 1998; 12: 861-6.
27. Jounela AJ, Lilja M, Lumme J, Morlin C, Hoyem A, Wessel-Aas T, et al. Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects. Blood Press 1994; 3: 231-5.
28. Magee PF, Preis ED. Is low dose hydrochlorthiazide effective? Hypertension 1996; 8 Suppl 2: 135-9.
29. Systolic Hypertension in the Elderly program (SHEP) Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated hypertension. Final results. JAMA 1991; 265: 3255-64.
30. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 1305-15.
31. Brown MJ, Palmer CR, Castaigne A, De Leeuw, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
32. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, et al. Randomized trial of old and new anti-hypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6.
33. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VII risk stratification. Hypertension 2000; 35: 1021-4.